One such predictive biomarker is the mutational status of the variable region of the immunoglobulin heavy chain (IGHV) gene, which is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT).

IGHV is the immunoglobulin heavy chain variable region genes; in B-cell neoplasms like chronic lymphocytic leukemia, mutations of IGHV are associated with better responses to some treatments and with prolonged survival.

Nov 5, 2021 · Previous studies have shown that CLL patients with mutated IGHV (M-IGHV) have a better prognosis, manifested in a longer time-to first treatment (TTFT) and overall survival (OS). Here we present an analysis on the impact of IGHV mutational status in an Israeli cohort of patients with CLL.

The immunoglobulin heavy chain gene (IgHV) mutation status correlates with the clinical outcome of patients with chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy. Why the survival rate of patients with unmutated IgHV is worse than that of …

Patients with chronic lymphocytic leukemia and unmutated immunoglobulin heavy-chain variable region gene (IGHV) have inferior survival from time of treatment in clinical studies. We assessed real-world outcomes based on mutational status and ...

Mar 4, 2025 · Fludarabine, Cytoxan and Rituxan (known as FCR) is the preferred treatment for patients under 65 years old with untreated IGHV-mutated CLL, according to NCCN. Learn more about SurvivorNet's rigorous medical review process.

Aug 12, 2019 · There are primarily two possible results with this assay. The first is unmutated IGHV, which is defined as the immunoglobulin heavy-chain sequence from the CLL having less than 2% difference in base pair sequences as compared to a reference germline sequence.

Jul 11, 2022 · We unveil the distinct patterns of IGHV repertoire and discuss the correlation between IGHV and other genetic abnormalities in LPL/WM. IGHV4 usage was a predictive marker of shorter progression-free survival in patients with LPL/WM.

May 25, 2022 · The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic lymphocytic...

Νext generation sequencing studies in Homo sapiens have identified novel immunoglobulin heavy variable (IGHV) genes and alleles necessitating changes in the international ImMunoGeneTics information system (IMGT) GENE-DB and reference directories of IMGT/V-QUEST.